FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
European Journal of Cancer（2022）
摘要
•FOLFIRI-ramucirumab is a safe and potent 2nd-line regimen.•FOLFIRI-ramucirumab is effective in docetaxel-pretreated patients.•FOLFIRI-ramucirumab is less-neurotoxic compared with paclitaxel-ramucirumab.
更多查看译文
关键词
Advanced gastroesophageal cancer,Ramucirumab,Irinotecan,Paclitaxel,FOLFIRI,Second line,Taxanes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要